Ennature Bio Pharma Lists on NSE & BSE; Reports FY26 Revenue of ₹246 Cr and EBITDA of ₹29 Cr
Ennature Bio Pharma Limited listed on the NSE and BSE on November 4, 2026, following its demerger from India Glycols Limited. In FY26, the company's biopharma division reported net revenue of ₹246 crore, EBITDA of ₹29 crore, and a gross margin of 40.1%. Plant-based APIs formed 67% of sales, while biopolymers and nutraceuticals contributed 16% and 17%, respectively. The company operates two manufacturing facilities in Dehradun (1,600 MT) and Kashipur (24,000 MT).
high confidence
What changedEnnature Bio Pharma has officially listed as an independent company on the NSE and BSE.
Why it mattersThe listing unlocks pure-play access to an integrated natural ingredients business with established global exports and proprietary extraction technology platforms.
FY26 Net Revenue: Rs 246 croreFY26 EBITDA: Rs 29 croreFY26 Gross Margin: 40.1%API Share of Sales: 67%Total Manufacturing Capacity: 25,600 MT
📅 Short termInitial trading sessions will establish price discovery and standalone valuation benchmarks relative to listed API and nutraceutical peers.
📈 Long termGrowth hinges on scaling branded nutraceutical products from 17% of revenue towards higher-margin formulations and expanding regulated market API registrations.
⚠ Risk flags
- High dependence on exports (over 50-80% across segments) exposing the company to global regulatory and currency risks
- Execution risk in expanding branded nutraceutical lines and clinical trials
👀 What to Watch
Track the upcoming quarterly financial results as a standalone listed entity and monitor margin expansion in the higher-value branded nutraceuticals segment.
